Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States
Authors:
- 22 December 2008
- journal article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 25 (2) , 401-411
Abstract
(2009). Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Current Medical Research and Opinion: Vol. 25, No. 2, pp. 401-411. doi: 10.1185/03007990802636817Keywords
This publication has 45 references indexed in Scilit:
- Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapyAnnals of Hematology, 2008
- Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic ReviewJournal of Clinical Oncology, 2007
- EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumoursEuropean Journal of Cancer, 2006
- Outpatient Oral Antibiotics for Febrile Neutropenic Cancer Patients Using a Score Predictive for ComplicationsJournal of Clinical Oncology, 2006
- 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice GuidelineJournal of Clinical Oncology, 2006
- Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapyCancer, 2005
- Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index scoreSupportive Care in Cancer, 2004
- Cost Effectiveness of Treatment Options in Advanced Breast Cancer in the UKPharmacoEconomics, 2001
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal of Cancer, 1993